Close

Cellect Biotechnology (APOP) Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

Go back to Cellect Biotechnology (APOP) Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

September 27, 2021 9:10 AM EDT

Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held Quoin Pharmaceuticals, a specialty pharmaceutical company focused on rare and orphan diseases, and all other proposals presented at the Special General Meeting of shareholders held on September 26, 2021, including the sale of the Companys subsidiary, Cellect Biotherapeutics Ltd, to EnCellX Inc. , a privately held company based in San Diego, CA. 

Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of... More